Topic: non-Hodgkin lymphoma
J&J and AbbVie’s Imbruvica hasn’t run into many stumbling blocks. But it has hit one in non-Hodgkin lymphoma.
Imbruvica is the only treatment for Waldenström's macroglobulinemia patients. But before competition hits, its makers are pushing for a wider market.
Another day, another approval for Merck immuno-oncology star Keytruda.
If the competition between Novartis and Gilead in relapsed large B-cell lymphoma comes down to price, it will be a close race.
Merck’s quest to move Keytruda further into blood cancers hit a snag over the summer, but now, it’s back on track.
Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.
Takeda and AZ will team up on Parkinson’s candidate, Samsung Bioepis got nod for a Humira copycat and Daiichi Sankyo said AZ buyout is “not the fact.”
Manufacturing costs are a significant factor in pricing CAR-T cancer meds because of the intensive process required for the personalized treatments.
J&J and Genmab have hit a snag in their quest for Darzalex expansion, throwing in the towel on a non-Hodgkin’s lymphoma trial.
Health authorities in the U.K. said CAR-T therapies could cost $649,000 to treat acute lymphoblastic leukemia in children.